Search

Your search keyword '"Al-Kuwari, Mohamed Ghaith"' showing total 241 results

Search Constraints

Start Over You searched for: Author "Al-Kuwari, Mohamed Ghaith" Remove constraint Author: "Al-Kuwari, Mohamed Ghaith"
241 results on '"Al-Kuwari, Mohamed Ghaith"'

Search Results

1. Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron

2. COVID-19 testing, incidence, and positivity trends among school age children during the academic years 2020–2022 in the State of Qatar: special focus on using CDC indicators for community transmission to evaluate school attendance policies and public health response

3. Prevalence of hepatitis B and C viruses among migrant workers in Qatar

4. Seroprevalence of herpes simplex virus type 1 and type 2 among the migrant workers in Qatar

6. Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study

7. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study

8. Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study

9. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study

10. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study

11. Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections

12. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

13. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

14. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

15. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals

16. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

17. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

18. BNT162b2 Versus mRNA‐1273 Vaccines: Comparative Analysis of Long‐Term Protection Against SARS‐CoV‐2 Infection and Severe COVID‐19 in Qatar.

22. Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant

23. Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient

24. Epidemiology of SARS-CoV2 in Qatar’s primary care population aged 10 years and above

27. SARS‐CoV‐2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study

29. History of primary-series and booster vaccination and protection against Omicron reinfection

30. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study

31. Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation.

33. A turning point in COVID-19 severity and fatality during the pandemic: A national cohort study in Qatar

34. Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: An observational study

35. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta infections

36. BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents

37. Short- and longer-term all-cause mortality among SARS-CoV-2- infected persons and the pull-forward phenomenon in Qatar

38. Effect of BNT162b2 antigen dosage on protection against SARS-CoV-2 omicron infection

39. 1966. Protection afforded by prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections.

40. COVID-19 primary series and booster vaccination and potential for immune imprinting

41. Duration of immune protection of SARS-CoV-2 natural infection against reinfection

43. Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections

44. Immune protection against SARS-CoV-2 re-reinfection and immune imprinting

45. Effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infection among children and adolescents in Qatar

46. Protection of SARS-CoV-2 natural infection against reinfection with the Omicron BA.4 or BA.5 subvariants

47. Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar

48. Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease

49. Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections

50. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar

Catalog

Books, media, physical & digital resources